Stereotaxis and ADAS 3D Combine Robotic Precision and Advanced Preoperative Substrate Mapping to Treat Cardiac Arrhythmias
November 01 2019 - 9:00AM
Stereotaxis (NYSE American: STXS) and ADAS 3D Medical SL today
announced the first patients have been successfully treated with
the integration of ADAS 3D’s advanced preoperative substrate
mapping and Stereotaxis’ Robotic Magnetic Navigation technologies.
ADAS 3D helps identify possible sources of
dangerous irregular heartbeats and provides a map to guide
physicians in delivering treatment. The software uses preoperative
cardiac MRI to generate detailed three-dimensional cardiac models
that identify arrhythmia substrate and characterize cardiac tissue.
The identification of fibrotic cardiac tissue and channels of
electrical conduction is particularly valuable for planning
Ventricular Tachycardia ablation procedures. It can also be used
during Atrial Fibrillation procedures to define the shape of the
Left Atrium and its fibrosis distribution, quantifying it and
improving guidance due to better identification of ablation
targets. The latest version of Stereotaxis software, recently
cleared for use in Europe and by the FDA, utilizes a software
interface that integrates ADAS 3D’s images and allows physicians to
utilize them to guide therapy during robotic cardiac ablation
procedures. The first integrated procedures were successfully
conducted by Prof. Pedro Adragao of Hospital da Luz in Lisbon,
Portugal.
“Life-threatening arrhythmias are common in
patients that have suffered a myocardial infarction. Cardiac
ablation can help these patients, but often require extensive
searching to find targets and widespread ablation to ensure all
problematic tissue has been addressed,” said Prof. Pedro Adragao.
“ADAS 3D supports rapid and precise identification of such tissue.
We have long recognized the clinical value of Robotic Magnetic
Navigation to treat patients with precision and safety. The
integration of both technologies should result in more effective,
rapid, and safe procedures for patients.”
“Combining our technology with Stereotaxis is an
exciting opportunity that we believe will positively impact the
field of Electrophysiology,” said Luis Serra, President of ADAS 3D
Medical. “The ability to translate combined MRI and CT images into
3D coordinates of the patient’s heart and then use robotics for
precision navigation of therapy should provide more reproducible
treatment during cardiac ablation. We hope this will benefit health
care professionals and their patients.”
“Stereotaxis is committed to advancing a robust
open ecosystem where physicians and patients benefit from the broad
integration of procedure data,” said David Fischel, CEO of
Stereotaxis. “We are excited to be working with ADAS 3D. The
combination of advanced diagnostic imaging with robotic navigation
is a step forward in the digitization of electrophysiology.”
About ADAS 3DADAS 3D MEDICAL SL, a company
based in Barcelona, is the recent offspring of the
electrophysiology business of Galgo Medical SL (Barcelona, Spain)
in partnership with Circle Cardiovascular Imaging Inc. (Calgary,
Canada). Its mission is to expand accessibility and use of Cardiac
Imaging (MRI and CT) to electrophysiology procedures such as Atrial
Fibrillation and Ventricular Tachycardia ablations. ADAS 3D
established itself as an early innovator in this field by
introducing software intended for the identification of arrhythmia
substrate and guidance of ablation treatment, for safer and more
efficient procedures. For more information, please visit
www.adas3d.com.
About StereotaxisStereotaxis is
the global leader in innovative robotic technologies designed to
enhance the treatment of arrhythmias and perform endovascular
procedures. Its mission is the discovery, development, and delivery
of robotic systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. Stereotaxis’ robotic technology has
received various regulatory clearances in the United States,
European Union, Japan, Canada, China, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not
limited to, the Company's ability to raise additional capital on a
timely basis and on terms that are acceptable, its ability to
continue to manage expenses and cash burn rate at sustainable
levels, its ability to continue to work with lenders to extend,
repay or refinance indebtedness, or to obtain additional financing,
in either case on acceptable terms, continued acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its systems and the timing of such purchases, competitive
factors, changes resulting from healthcare reform in the United
States, including changes in government reimbursement procedures,
dependence upon third-party vendors, timing of regulatory
approvals, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments in any particular period or at all because some
of these purchase orders and other commitments are subject to
contingencies that are outside of the Company's control. In
addition, these orders and commitments may be revised, modified,
delayed or canceled, either by their express terms, as a result of
negotiations, or by overall project changes or delays.
Stereotaxis: |
|
ADAS 3D: |
David Fischel |
|
Luis Serra |
Chairman and CEO |
|
President |
|
|
|
Kimberly Peery |
|
Jacobo Gil de Biedma |
CFO |
|
Business Development Director |
|
|
|
314-678-6100 |
|
+34-93-3283964 |
investors@stereotaxis.com |
|
info@adas3d.com |
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Apr 2023 to Apr 2024